COMPANY PROFILE
Selvita delivers comprehensive solutions to customers from the pharmaceutical and biotechnology industry targeted at speedy and cost-effective introduction of efficacious and safe drugs to the market.
The areas of activity include:
Selvita is also the majority shareholder of BioCentrum (www.biocentrum.com.pl), which provides preclinical ADMET services, and biopharmaceutical development services. Selvita Group laboratories have the General Pharmaceutical Inspectorate accreditation and Good Laboratory Practice (GLP) certification.
Selvita develops its own innovative drugs, which originate from research at Polish universities and later commercializes them with partners from the pharmaceutical industry. Selvita is involved in several research projects at the pre-clinical stage. Their current projects are in the area of oncology and central nervous system.
They employ over 180 top-class professionals from the area of medicine, chemistry, pharmacy, molecular biology, biotechnology and informatics, and almost 40 percent of Selvita employees hold a PhD degree in the field of biomedical research. Many of their experts have several years of experience in the biotechnology and pharmaceutical companies in the US, Canada, UK, Germany and Poland, and publications in the best scientific journals such as: Nature Biotechnology, Science, and the Journal of Medicinal Chemistry. They work with leading universities and research centers from Poland, Europe and United States.
In their work they adhere to the highest ethical standards, both in dealing with the environment and within the company. Their goal is to develop solutions that contribute to the extension and improvement of the quality of life. In doing so, Selvita is guided by the respect for human life at it’s every stage, and does not conduct research that violates human dignity.
ADMINISTRATIVE DATA
Selvita S.A.
Bobrzyńskiego 14
30-348 Kraków
Poland
Email: selvita@selvita.com
www: http://www.selvita.com
Paweł Przewięźlikowski, CEO of Selvita, the largest biotech company between Germany and India, discusses the first-in-class and pioneer Polish molecule, SEL24, and the future game changing molecule, SEL120 – the…
Selvita is one of Poland’s R&D jewels, and its co-founder and CEO, Paweł Przewięźlikowski, strongly wishes that others would join their efforts in finally raising Poland’s footprint in R&D. He…
Selvita is one of Poland’s R&D jewels, and its co-founder and CEO, Paweł Przewięźlikowski, strongly wishes that others would join their efforts in finally raising Poland’s footprint in R&D. He…
Selvita is one of Poland’s R&D jewels, and its co-founder and CEO, Paweł Przewięźlikowski, strongly wishes that others would join their efforts in finally raising Poland’s footprint in R&D. He…
Philippe Coudiere, general manager of Pierre Fabre Dermo-cosmetics Poland, highlights the key partnerships the company has nurtured with pharmacists and dermatologists and the importance of clinical data for their products.…
Artur Chabowski, president of Mabion, a pioneer Polish biotech player, discusses the historic partnership of their product, MabionCD20 with Mylan for the EU and Baltic states and the opportunities this…
Markus Sieger, CEO of Polpharma, outlines his global strategy for the company, focused on OTC and CHC, internationalization and a strong R&D strategy to push forward biosimilars. Furthermore, he highlights…
Mariusz Ignatowicz, PwC healthcare sector leader for CEE, discusses the funding of the Polish healthcare ecosystem and the need to find an alternative payer in the long-term Additionally, he highlights…
Colm Murphy, general plant manager of Anpharm, a key European production site for the Servier group, highlights major investments in recent years, such as the state-of-the-art QC Lab, and his…
Krzysztof Kołodziejski, country manager of Santen Poland, discusses the strategy he put in place to modernize the business culture of the affiliate and how this has led to great success.…
Jarosław Król, president of Polfa Tarchomin, highlights the strategic moves he has made to stabilise the company and the need to deliver a new, fresh portfolio to drive forward profit.…
Andrzej Tarnkowski, founder and owner of Antar, a Polish success story within the orthopaedic field, discusses the company’s successful international expansion into various markets, including Germany, while highlighting the opening…
Joanna Drewla, general manager of Servier Poland, discusses Polish healthcare challenges and looks at areas for improvement to create a sustainable balance for market access of innovative treatments. Furthermore, she…
Stefan Jaworski-Martycz, country manager Poland and CEE Cluster Lead of Théa, a leading French ophthalmology company, discusses the intricacies of the Polish ophthalmology environment and the key steps for the…
Dorota Hryniewiecka-Firlej, president of Pfizer Poland, discusses the current state of the Polish innovation landscape and importance of a tight-knit relationship between the innovative pharmaceutical market and the government for…
Robert Bitner, country manager of Galderma Poland, give his first impressions of the Polish dermatology landscape and how his past experiences have prepared him for the challenges ahead. Additionally, he…
See our Cookie Privacy Policy Here
